Privia Health Group, Inc. (NASDAQ:PRVA) Shares Sold by Harbor Capital Advisors Inc.

Harbor Capital Advisors Inc. lessened its stake in Privia Health Group, Inc. (NASDAQ:PRVA) by 11.6% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 24,705 shares of the company’s stock after selling 3,246 shares during the quarter. Harbor Capital Advisors Inc.’s holdings in Privia Health Group were worth $483,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Canada Pension Plan Investment Board purchased a new position in Privia Health Group in the second quarter valued at approximately $26,000. GAMMA Investing LLC boosted its holdings in shares of Privia Health Group by 98.7% in the 3rd quarter. GAMMA Investing LLC now owns 1,701 shares of the company’s stock valued at $31,000 after buying an additional 845 shares in the last quarter. Quarry LP grew its position in shares of Privia Health Group by 344.6% in the 3rd quarter. Quarry LP now owns 3,268 shares of the company’s stock valued at $60,000 after buying an additional 2,533 shares during the last quarter. KBC Group NV raised its stake in Privia Health Group by 34.6% during the 3rd quarter. KBC Group NV now owns 3,385 shares of the company’s stock worth $62,000 after acquiring an additional 871 shares in the last quarter. Finally, Neo Ivy Capital Management purchased a new stake in Privia Health Group in the third quarter valued at $66,000. 94.48% of the stock is owned by institutional investors and hedge funds.

Privia Health Group Price Performance

Shares of PRVA stock opened at $21.00 on Wednesday. The business’s fifty day moving average price is $20.99 and its 200 day moving average price is $19.52. The firm has a market capitalization of $2.52 billion, a PE ratio of 210.02, a P/E/G ratio of 5.45 and a beta of 0.85. Privia Health Group, Inc. has a 1-year low of $15.92 and a 1-year high of $23.24.

Wall Street Analyst Weigh In

Several brokerages have issued reports on PRVA. Stephens reaffirmed an “overweight” rating and set a $26.00 price objective on shares of Privia Health Group in a report on Thursday, January 2nd. JPMorgan Chase & Co. raised their price target on Privia Health Group from $27.00 to $28.00 and gave the stock an “overweight” rating in a research note on Friday, November 29th. KeyCorp assumed coverage on Privia Health Group in a research note on Friday, October 11th. They issued an “overweight” rating and a $23.00 price objective for the company. Truist Financial raised their target price on shares of Privia Health Group from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Finally, Barclays upped their price target on shares of Privia Health Group from $19.00 to $21.00 and gave the company an “equal weight” rating in a research report on Friday, November 8th. Two research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $24.88.

Privia Health Group Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.